Broad tumor antigens (presented by genetically modified allogeneic whole tumor cell lines)

Broad tumor antigens presented by genetically modified allogeneic whole tumor cell lines represent a polyvalent approach to cancer immunotherapy (National Cancer Institute, 2024). This strategy utilizes a library of tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) inherent to the whole cell rather than a single protein (Lutz et al., 2014). These allogeneic cell lines are often genetically engineered to express immunostimulatory molecules, such as Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), or to inhibit immunosuppressive factors like TGF-beta (Nemunaitis et al., 2006). When administered to a patient, these cells serve as an "antigen factory," prompting the host's immune system to recognize and mount a response against similar antigens present on the patient's own endogenous tumor cells (Hardacre et al., 2013). This approach aims to overcome tumor heterogeneity and prevent immune escape by inducing a broad T-cell and B-cell mediated response. The use of allogeneic cells allows for an "off-the-shelf" product that provides a wide array of shared antigens across different patients with the same tumor type. Clinical trials have investigated this modality in various cancers, including pancreatic, prostate, and non-small cell lung cancer (Nemunaitis et al., 2009). The primary goal is to convert the tumor microenvironment from immunosuppressive to immunostimulatory, facilitating a robust anti-tumor attack.

Other names

Allogeneic whole-cell tumor vaccine antigensPolyvalent tumor antigensGVAX-associated antigensTumor-associated antigensTumor-specific antigens

Induction of a polyvalent immune response through the presentation of a broad spectrum of tumor antigens in an immunostimulatory environment (e.g., GM-CSF secretion), leading to the activation of tumor-specific T-cells and B-cells.